Nymox says data supports Alzheimer's disease test, get $15m for BHP
This article was originally published in Clinica
Executive Summary
A paper published in the January 2008 issue of Expert Review of Molecular Diagnostics concludes that Nymox Pharmaceutical's AlzheimAlert urine test "adds significant useful information in the diagnosis of Alzheimer's disease particularly for the family physician". The FDA has repeatedly refused to grant US marketing authorisation for the test, which detects strands of neural thread protein in urine (see Clinica No 1168, p 20). Nymox markets the test in Europe and offers it in the US as a CLIA-certified diagnostic service. Separately, the company said it had secured $15m in financial commitments. Nymox said it will use the funds to develop its NX-1207 drug for benign prostate hyperplasia and other new products.